(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/159092 A1

(51) International Patent Classification:
A61P 3/00 (2006.01) *A61P 43/00* (2006.01)
A61K 47/61 (2017.01)

(21) International Application Number:
PCT/US2021/017113

(22) International Filing Date:
08 February 2021 (08.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/971,930 08 February 2020 (08.02.2020) US
63/115,975 19 November 2020 (19.11.2020) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 50 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors; and

(71) Applicants: **AN HAACK, Kristina** [FR/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **FINN, Patrick** [US/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US).

(74) Agent: **QI, Yan**; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title:** COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE




FIG. 1

(57) **Abstract:** The present application provides methods of treating Pompe disease such as infantile- onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid a-glucosidase (GAA) conjugate, such as avalglucosidase alfa. Also provided are formulations of the oligosaccharide-GAA conjugates.

WO 2021/159092 A1